# Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant

> **NCT05477108** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 108 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** Treatment A (BGF MDI HFO with oral activated charcoal)
- **DRUG:** Treatment B (BGF MDI HFA with oral activated charcoal)

## Key facts

- **NCT ID:** NCT05477108
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-29
- **Primary completion:** 2023-04-11
- **Final completion:** 2023-04-11
- **Target enrollment:** 108 (ACTUAL)
- **Last updated:** 2025-08-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05477108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05477108, "Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05477108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*